Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
autism spectrum disorders
Biotech
MapLight turns off preclinical tap to fund schizophrenia drug
Despite mixed results for its experimental schizophrenia treatment, MapLight is going all-in on the asset—at the expense of its preclinical programs.
James Waldron
Aug 14, 2026 4:38am
NeuroQure debuts test to ID autism risk at birth
Jan 22, 2026 4:50am
LinusBio launches autism diagnostic using single strand of hair
Feb 6, 2025 11:00am
MARAbio’s antibody test for autoimmune-related autism nets $19M
Oct 7, 2024 10:00am
Beyond Air looks beyond lungs to target nitric oxide in autism
Jun 20, 2023 10:54am
Stalicla pledges $270M for Novartis' failed fragile X asset
Jan 9, 2023 8:06am
